Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)

The summary for the Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21): -The Pilot and Feasibility Clinical Research Grants Program is designed to support short-term clinical pilot studies and planning activities to help stimulate the translation of promising research developments from the laboratory into clinical practice for diabetes, endocrine and metabolic diseases. -The Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases invites applications for the exploratory/developmental (R21) grant mechanism in selected areas of opportunity within our mission. The intent of this initiative is to encourage researchers to apply novel technologies, develop new tools, biomarkers and model systems, and test innovative concepts of potential diagnostic and therapeutic relevance to diseases within our mission including diabetes and its complications, obesity, endocrine disorders including osteoporosis, and inborn errors of metabolism including cystic fibrosis. The R21 mechanism is intended to encourage exploratory research projects by providing support at the conceptual stages of these projects. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. -Project Period and Award Levels: The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over the two years of the R21 award, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. -This announcement uses the NIH exploratory/developmental grant (R21) award mechanism. -Eligible organizations: For-profit or non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Units of State and local governments; Eligible agencies of the Federal government; Domestic or foreign institutions; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization. -Eligible Project Directors/Principal Investigators (PD/PIs):Any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. -Applicants may submit more than one application, provided they are scientifically distinct. -An R21 is not renewable.